Loading
A phase 3 trial of pemetrexed in lung cancer, run by Guangzhou JOYO Pharma Co., Ltd, not yet recruiting.
JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. is a phase 3, randomised interventional study registered as NCT07154368 by Guangzhou JOYO Pharma Co., Ltd, with a registry enrolment figure of 207 participants, started 2025-09-23 and due to reach its primary completion in 2027-10-31. Interventions recorded: Pemetrexed injection; Cross-over to JYP0322; JYP0322 tablets. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS) by BICR Assessment. Lung eligibility wording from the registry: "* Subjects with histologically or cytologically documented NSCLC". No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares ROS1-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares ROS1-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.